Nuo Therapeutics Inc. Stock Analysis AURX

Nuo Therapeutics, Inc. engages in the development and sale of biomedical products for chronic wound care. The company is headquartered in Houston, Texas. The company went IPO on 2017-01-19. The firm is focused on developing and marketing products for chronic wound care primarily within the United States. The company has commercialized cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The firm's product, Aurix, is a biodynamic hematogel that uses a patient’s own platelets and plasma as a catalyst for healing. Its commercial offering consists of a point of care technology for the separation of autologous blood to produce a platelet-based therapy for use in the chronic wound care market. The Aurix System produces a platelet-rich plasma (PRP) gel at the point of care using the patient’s own platelets and plasma sourced from a small draw of peripheral blood. The Aurix PRP comprises a natural, endogenous complement of protein and non-protein signal molecules that are believed to contribute to effective healing.